Schilke Tobin, CF, IO, reported a transaction classified as return at Crinetics Pharmaceuticals, Inc. involving 7956.000000 shares for an estimated $676260.00. Reported holdings after the transaction were 71471.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
Chief Financial & Infra. Ofcr.
Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceut…
The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive…
The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effectiv…
The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Co…
0 other filings
0 recent txs